Open $33.59
Day Range 33.56 - 33.88
52 Week Range 17.00 - 40.84
Market Cap $1.61B
Shares Outstanding 47.91M
Public Float 37.29M
Beta 0.82
Rev. per Employee N/A
P/E Ratio N/A
EPS -$3.03
Yield N/A
Dividend N/A
Ex-Dividend Date N/A
Short Interest 7.65M 05/14/21
% of Float Shorted 20.52%
Average Volume 1M

5 Day	70.82%
1 Month	62.69%
3 Month	28.62%
YTD	17.50%
1 Year	-9.49%

Sell
Under
Hold
Over
Buy

Number of Ratings 10 Full Ratings

MarketWatch
Dow Jones

Constellation Pharmaceuticals downgraded to hold from buy at Truist

Jun. 4, 2021 at 8:23 a.m. ET by Tomi Kilgore

Constellation Pharmaceuticals downgraded to market perform at BMO Capital

Jun. 3, 2021 at 8:58 a.m. ET by Tomi Kilgore

Barron's

MorphoSys Fell Too Far After M&A News, Analyst Says

Jun. 3, 2021 at 8:27 a.m. ET by Barron's

Barron's

MorphoSys Buys Constellation Pharma in $1.7B Deal. Is Biotech M&A Back?

Jun. 2, 2021 at 10:50 a.m. ET by Barron's

MorphoSys to buy Constellation Pharma for $1.7 billion; Constellation's stock soars 61%

Jun. 2, 2021 at 7:53 a.m. ET by Jaimy Lee

MorphoSys to Buy Constellation Pharmaceuticals for $1.7 Billion >MOR CNST

Jun. 2, 2021 at 7:53 a.m. ET

Constellation Pharmaceuticals upgraded to outperform from market perform at BMO Capital

Jan. 25, 2021 at 9:19 a.m. ET by Tomi Kilgore

Constellation Pharmaceuticals stock price target cut to $20 from $47 at Oppenheimer

Sep. 8, 2020 at 8:46 a.m. ET by Tomi Kilgore

Constellation Pharmaceuticals downgraded to perform from outperform at Oppenheimer

Sep. 8, 2020 at 8:46 a.m. ET by Tomi Kilgore

Constellation Pharmaceuticals started at buy with $50 stock price target at SunTrust RH

Feb. 13, 2020 at 8:18 a.m. ET by Tomi Kilgore

Constellation Pharmaceuticals downgraded to market perform from outperform at BMO Capital

Jan. 9, 2020 at 11:45 a.m. ET by Tomi Kilgore

Here are the best-performing Nasdaq stocks of 2019

Dec. 28, 2019 at 9:06 a.m. ET by Philip van Doorn

Constellation shares soar 95% after promising data from rare disease trial

Nov. 6, 2019 at 11:35 a.m. ET by Jaimy Lee

Constellation Pharmaceuticals stock up 138%

Nov. 6, 2019 at 10:36 a.m. ET by Ciara Linnane

Constellation Pharmaceuticals started at outperform with $21 stock price target at Oppenheimer

Aug. 13, 2018 at 8:42 a.m. ET by Tomi Kilgore

Constellation Pharmaceuticals started at overweight with $17 stock price target at J.P. Morgan

Aug. 13, 2018 at 7:39 a.m. ET by Tomi Kilgore

Constellation Pharmaceuticals shares slide 25% in trading debut

Jul. 19, 2018 at 11:47 a.m. ET by Ciara Linnane

Constellation Pharmaceuticals shares slide 25% in trading debut

Jul. 19, 2018 at 11:44 a.m. ET by Ciara Linnane

Constellation Pharmaceuticals IPO prices at midpoint, but shares offered cut by 25%

Jul. 19, 2018 at 7:56 a.m. ET by Tomi Kilgore

Constellation Pharmaceuticals to offer 5.34 million shares in IPO, priced at $14 to $16 each

Jul. 9, 2018 at 6:54 a.m. ET by Ciara Linnane

No Headlines Available

Other News
Press Releases

Why MorphoSys Stock Sank This Week

Jun. 3, 2021 at 7:07 p.m. ET on Motley Fool

Why Constellation Pharmaceuticals Stock Was Crushing It This Week

Jun. 3, 2021 at 6:50 p.m. ET on Motley Fool

Constellation (CNST) Surges on Takeover Deal With MorphoSys

Jun. 3, 2021 at 1:16 p.m. ET on Zacks.com

Why Constellation Pharmaceuticals Stock Is Skyrocketing Today

Jun. 2, 2021 at 12:16 p.m. ET on Motley Fool

Robert W. Baird Thinks Constellation Pharmaceuticals’ Stock is Going to Recover

May. 13, 2021 at 4:08 a.m. ET on SmarterAnalyst

RBC Capital Thinks Constellation Pharmaceuticals’ Stock is Going to Recover

May. 11, 2021 at 9:47 p.m. ET on SmarterAnalyst

H.C. Wainwright Thinks Constellation Pharmaceuticals’ Stock is Going to Recover

May. 11, 2021 at 6:26 a.m. ET on SmarterAnalyst

Analysts Offer Insights on Healthcare Companies: Constellation Pharmaceuticals (CNST) and Surgalign Holdings (SRGA)

May. 10, 2021 at 9:55 p.m. ET on SmarterAnalyst

Constellation Pharmaceuticals (CNST) Q1 2021 Earnings Call Transcript

May. 10, 2021 at 5:30 p.m. ET on Motley Fool

Analysts Offer Insights on Healthcare Companies: Constellation Pharmaceuticals (CNST), Aurinia Pharmaceuticals (AUPH) and Masimo (MASI)

Feb. 26, 2021 at 4:04 a.m. ET on SmarterAnalyst

Constellation Pharmaceuticals (CNST) Gets a Buy Rating from Robert W. Baird

Feb. 25, 2021 at 11:19 a.m. ET on SmarterAnalyst

RBC Capital Thinks Constellation Pharmaceuticals’ Stock is Going to Recover

Nov. 16, 2020 at 7:33 a.m. ET on SmarterAnalyst

Why Constellation Pharmaceuticals (CNST) Might Surprise This Earnings Season?

Aug. 4, 2020 at 11:08 a.m. ET on Zacks.com

Steven Cohen Homes in on Otonomy by Expanding Stake

Jul. 15, 2020 at 11:15 a.m. ET on GuruFocus.com

Constellation Pharmaceuticals, Inc. (CNST) Upgraded to Buy: What Does It Mean for the Stock?

May. 25, 2020 at 12:00 p.m. ET on Zacks.com

Is Constellation (CNST) Stock a Solid Choice Right Now?

May. 14, 2020 at 9:24 a.m. ET on Zacks.com

What Makes Constellation Pharmaceuticals, Inc. (CNST) a New Buy Stock

Apr. 24, 2020 at 12:00 p.m. ET on Zacks.com

Why You Shouldn't Bet Against Constellation Pharmaceuticals (CNST) Stock

Mar. 24, 2020 at 8:58 a.m. ET on Zacks.com

What Makes Constellation Pharmaceuticals, Inc. (CNST) a New Buy Stock

Mar. 16, 2020 at 12:00 p.m. ET on Zacks.com

Biotech Rally Sends Nasdaq to 9000: ETFs in Focus

Dec. 27, 2019 at 2:19 p.m. ET on Zacks.com

No Headlines Available

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA.